Skip to main content
Bruce Cree, MD, Neurology, San Francisco, CA, UCSF Medical Center

BruceA.CreeMD

Neurology San Francisco, CA

Neuroimmunology/Multiple Sclerosis

Associate Clinical Professor, Neurology, UCSF School of Medicine

Dr. Cree is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Cree's full profile

Already have an account?

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 1998 - 2001
  • California Pacific Medical Center
    California Pacific Medical CenterInternship, Internal Medicine, 1997 - 1998
  • University of California San Francisco School of Medicine
    University of California San Francisco School of MedicineClass of 1997

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2001 - 2024
  • American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Optimizing the Risk-Benefit Therapeutic Equation for Multiple Sclerosis 
    CMEducation Resources, LLC, Pittsburgh, Pennsylvania - 5/4/2013
  • Optimizing the Risk-Benefit Therapeutic Equation for Multiple Sclerosis 
    CMEducation Resources, LLC, Cleveland, Ohio - 4/27/2013
  • Optimizing the Risk-Benefit Therapeutic Equation for Multiple Sclerosis 
    CMEducation Resources, LLC, Denver, Colorado - 4/20/2013
  • Join now to see all

Press Mentions

  • New Analysis of MRI Findings Show Uplizna Reduced the Formation of Asymptomatic Optic Nerve Lesions in People with NMOSD
    New Analysis of MRI Findings Show Uplizna Reduced the Formation of Asymptomatic Optic Nerve Lesions in People with NMOSDMarch 15th, 2023
  • New Data Suggest Uplinza for the Treatment of NMOSD Did Not Increase the Risk of COVID-19 or Reduce Antibody Levels from Childhood Vaccines
    New Data Suggest Uplinza for the Treatment of NMOSD Did Not Increase the Risk of COVID-19 or Reduce Antibody Levels from Childhood VaccinesFebruary 28th, 2023
  • New Analysis of UPLIZNA® (Inebilizumab-Cdon) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks
    New Analysis of UPLIZNA® (Inebilizumab-Cdon) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) AttacksOctober 26th, 2022
  • Join now to see all

Hospital Affiliations